Marshall Wace, LLP Oramed Pharmaceuticals Inc. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Oramed Pharmaceuticals Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 22,527 shares of ORMP stock, worth $53,614. This represents 0.0% of its overall portfolio holdings.

Number of Shares

22,527

Holding current value

$53,614

% of portfolio

0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.21 - $2.63 $49,784 - $59,246	22,527 New	22,527 $54,000
Q1 2023 May 15, 2023	SELL	$1.93 - $13.1 $51,812 - $351,682	-26,846 Reduced 71.78%	10,553 $23,000
Q4 2022 Feb 14, 2023	BUY	$5.88 - $12.03 $52,861 - $108,149	8,990 Added 31.64%	37,399 $449,000
Q3 2022 Nov 14, 2022	BUY	$4.6 - $9.91 $40,940 - $88,199	8,900 Added 45.62%	28,409 $185,000
Q2 2022 Aug 15, 2022	BUY	$3.72 - $9.0 $72,573 - $175,581	19,509 New	19,509 $90,000
Q2 2021 Aug 13, 2021	SELL	$8.34 - $14.59 $96,435 - $168,704	-11,563 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$4.22 - $11.33 $105,791 - $284,031	-25,069 Reduced 68.43%	11,563 $117,000
Q4 2020 Feb 16, 2021	SELL	$2.48 - $4.64 $54,599 - $102,154	-22,016 Reduced 37.54%	36,632 $155,000
Q3 2020 Nov 16, 2020	BUY	$2.58 - $4.16 $26,801 - $43,214	10,388 Added 21.53%	58,648 $153,000
Q2 2020 Aug 13, 2020	SELL	$2.87 - $4.12 $83,519 - $119,896	-29,101 Reduced 37.62%	48,260 $170,000
Q1 2020 May 15, 2020	SELL	$2.6 - $5.5 $94,497 - $199,897	-36,345 Reduced 31.96%	77,361 $235,000
Q4 2019 Feb 14, 2020	BUY	$2.43 - $5.74 $276,305 - $652,672	113,706 New	113,706 $586,000

Others Institutions Holding ORMP

# of Institutions

Shares Held

7.4M

Call Options Held

Put Options Held

2.1K

View Full List

About ORAMED PHARMACEUTICALS INC.

Ticker ORMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,100
Market Cap $92.4M
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...

More about ORMP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account